Acelyrin (SLRN) to Release Quarterly Earnings on Tuesday

Acelyrin (NASDAQ:SLRN) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Trading Down 4.1 %

Shares of Acelyrin stock traded down $0.11 during trading hours on Tuesday, reaching $2.44. 15,482 shares of the company’s stock were exchanged, compared to its average volume of 1,204,024. The firm has a market capitalization of $245.71 million, a price-to-earnings ratio of -0.99 and a beta of 1.07. Acelyrin has a 52-week low of $1.85 and a 52-week high of $7.25. The company has a fifty day moving average of $2.47 and a 200-day moving average of $3.20.

Insider Transactions at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.60% of the company’s stock.

Analyst Upgrades and Downgrades

SLRN has been the subject of several research analyst reports. HC Wainwright dropped their price target on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Citigroup reduced their target price on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Acelyrin has a consensus rating of “Hold” and an average price target of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.